Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01484925 · ClinicalTrials.gov registry record

BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus

A clinical trial of Barrett's Esophagus, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
60
Enrollment target
1
Study location

NCT01484925: Completed study of Barrett's Esophagus, sponsored by Abramson Cancer Center at Penn Medicine.

NCT01484925 is a study of Barrett's Esophagus that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 60 participants, below the 522-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01484925, a study of Barrett's Esophagus, has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

This research study hopes to identify new molecular markers in the tissue of Barrett's esophagus that will help physicians better understand and manage this condition. Patients undergoing an upper endoscopy will be asked to complete a gastroesophageal reflux disease (GERD) questionnaire, provide a blood sample and allow additional biopsies to be taken during the procedure.

Conditions Studied

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2011-11
Est. Completion 2018-11

What the finished NCT01484925 record still lists

NCT01484925 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 522-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Barrett's Esophagus appearing as the primary indexed condition, and to 0 interventions.

NCT01484925 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01484925 about?

NCT01484925 is a clinical study titled "BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus". This research study hopes to identify new molecular markers in the tissue of Barrett's esophagus that will help physicians better understand and manage this condition. Patients undergoing an upper endoscopy will be asked to complete a gastroesophageal reflux disease (GERD) questionnaire, provide a b...

What is the current status of trial NCT01484925?

This trial is currently completed. The enrollment target is 60 participants. The study started on 2011-11. Estimated completion is 2018-11.

What conditions does trial NCT01484925 study?

This clinical trial studies the following conditions: Barrett's Esophagus.

Who is sponsoring clinical trial NCT01484925?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01484925 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Barrett's Esophagus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01484925's enrollment target sits among peer trials

60 13th of 22 higher than 9 of 22 other Barrett's Esophagus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Barrett's Esophagus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01484925, the US trial registry maintained by the National Library of Medicine. NCT01484925 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.